Holistic Needs Assessment in Brain Cancer Patients: A Systematic Review of Available Tools

Afseth, Janyne; Neubeck, Lis; Karatzias, Thanos; Grant, Robin

doi:10.1093/neuonc/nox238.051

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found four clinical tools: the Brain Patient Concern Inventory (Brain PCI),72 the MDASI-BT,67,76 the NFbrSI-24,71 and the Supportive Care Needs Survey 34 plus brain subscale (SCNS34-BS), as seen in Table 2. The Brain PCI and SCNS34-BS were designed for clinical use and HNA prior to visits but needed psychometric testing, whereas the MDASI-BT and NFbrSI-24 are psychometric-tested symptom assessment tools but would need further development to be used for HNA 77…”

Section: Resultsmentioning

confidence: 99%

<p>Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma</p>

Rosenlund¹,

Degsell²,

Jakola³

2019

PROM

View full text Add to dashboard Cite

BackgroundPersons with high-grade glioma face both neurological and cancer-related symptoms from the tumor itself and its treatment affecting their daily lives. Survival alone is not an adequate outcome, the quality of the survivorship experience needs to be regarded with equal importance. Patient-reported outcome (PRO) measures can be used to evaluate treatment effects and symptom management interventions.PurposeThe aim of this review was to identify the use, challenges, and potential of PRO measures in survivors of high-grade glioma.MethodsA narrative expert opinion review was performed on the subject. In addition to our own experiences we searched PubMed, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and PsycINFO for brain tumor-specific PRO measures used in the population of adult patients with high-grade glioma, both original articles and reviews were included.ResultsThere are several PRO measures that have been validated for patients with primary brain tumors including high-grade glioma. PRO measures are used both in clinical trials to evaluate the effect of treatment on health-related quality of life, and in daily clinical practice for holistic needs assessment and symptom management. Common PRO measures used for patients with high-grade glioma are European Organization for Research and Treatment of Cancer general instrument for patients with cancer together with brain tumor module, Functional Assessment of Cancer Therapy-Brain, and MD Anderson Symptom Inventory for Brain Tumor. Neurologic and cognitive disorders often occur in patients with high-grade glioma, which affects patients’ ability to self-report over time, making it more challenging in this population. PRO as a primary outcome seems underutilized.ConclusionFor clinical research, PRO measures need to be used together with other clinical outcome measures rather than replacing traditional outcome measures. Moving to more use of PRO measures in survivorship care has potential to improve patient-caregiver-healthcare team communication, symptom management, and quality of care. Implementing PROs in survivorship care should also involve caregivers and a response based on the results.

show abstract

Section: Resultsmentioning

confidence: 99%

<p>Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma</p>

Rosenlund¹,

Degsell²,

Jakola³

2019

PROM

View full text Add to dashboard Cite

show abstract

“…Radiation therapy has a central role in the management of malignant brain tumors, especially for the most aggressive ones [2][3][4]. First introduced in 1936 by Locher [5], the Boron Neutron Capture Therapy model (BNCT) is a promising type of radiation therapy for cancer that has the potential to be an important treatment for numerous types of tumors, including for those lying in areas that are difficult to access for surgery intervention, such as high-grade gliomas and metastatic brain tumors [6][7][8] Currently, only two low molecular weight boron-containing compounds, sodium mercapto-undecahydro-closo-dodecaborate (BSH, developed in about 1965) and a water-soluble fructose complex of borylphenylalanine (BPA, discovered in 1958), have been approved and found clinical use in BNCT [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

“Free of Base” Sulfa-Michael Addition for Novel o-Carboranyl-DL-Cysteine Synthesis

et al. 2020

View full text Add to dashboard Cite

The sulfa-Michael addition reaction was applied for the two-step synthesis of o-carboranyl cysteine 1-HOOCCH(NH2)CH2S-1,2-C2B10H11 from the trimethylammonium salt of 1-mercapto-o-carborane and methyl 2-acetamidoacrylate. To avoid the decapitation of o-carborane into its nido-form, the “free of base” method under mild conditions in a system of two immiscible solvents toluene-H2O was developed. The replacement of H2O by 2H2O resulted in carboranyl-cysteine containing a deuterium label at the α-position of the amino acid 1-HOOCCD(NH2)CH2S-1,2-C2B10H11. The structure of the protected o-carboranyl cysteine was determined by single-crystal X-ray diffraction. The obtained compounds can be considered as potential agents for the Boron Neutron Capture Therapy of cancer.

show abstract

Holistic Needs Assessment in Brain Cancer Patients: A Systematic Review of Available Tools

Cited by 2 publications

References 0 publications

<p>Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma</p>

<p>Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma</p>

“Free of Base” Sulfa-Michael Addition for Novel o-Carboranyl-DL-Cysteine Synthesis

Contact Info

Product

Resources

About